Drug
Dnl593
Dnl593: highest development phase Phase 1/2, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL593 NCT05262023 | Phase 1/2 | Frontotemporal Dementia |
Latest
No recent events.
Follow Dnl593 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.